AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data
AstraZeneca and its roxadustat partner FibroGen headed into a high-stakes FDA expert meeting this week after receiving tough safety questions about the med from agency staffers. The daylong event Thursday featured bruising feedback, and their application now faces even more uncertainty. In a 13 to 1 vote, FDA committee panelists said that the drug should not be approved… Read More »